This webinar will discuss the following topics:
- Surveillance after allograft transplantation is critical to the detection of active rejection and prevention of chronic allograft dysfunction.
- Levels of donor derive cell-free DNA (dd-cfDNA) have been observed significantly increased in active rejection versus stable patients, which is related to differences on allograft injury compared to a normal healthy status.
- By using single-nucleotide polymorphisms (SNPs) to discriminate between donor and recipient cfDNA molecules, AlloSeq cfDNA assay measures dd-cfDNA based as a clinical-grade, next-generation targeted sequencing (NGS) assay.
- Measurement of plasma dd-cfDNA at consecutive time points after transplant is a clinically useful tool for the assessment of allograft health and non-invasive surveillance for injury.
- Negative results are strongly supportive of no active injury (high NPV of 95%) and can give patients peace of mind. For transplant physicians, the test offers an opportunity to rule out rejection, and prioritise patients based on low risk for telemedicine approaches
Who should attend?
Transplant physicians; transplant immunologists; transplant coordinators; health care innovation officers
Creators and Moderators:
CareDX – Creator
Silvia Casas | Barcelona, Spain – Moderator
Miha Arnol | Ljubljana, Slovenia
Andrea Zajacova | Prague, Czech Republic
Jeroen Verhoeven | Rotterdam, Netherlands
This webinar is organised in partnership with and sponsored by CareDx.